Axogen Sustainability Profile
Axogen, Inc., headquartered in the United States, is a leading innovator in the field of regenerative medicine, specialising in peripheral nerve repair. Founded in 2002, the company has made significant strides in advancing surgical solutions for nerve injuries, with a focus on providing high-quality products that enhance patient outcomes. With a robust portfolio that includes Axoguard® Nerve Connector and Avance® Nerve Graft, Axogen stands out for its commitment to utilising human tissue for nerve repair, setting it apart from traditional synthetic alternatives. The company has established a strong market position, recognised for its pioneering contributions to nerve regeneration and repair. Operating primarily in North America, Axogen continues to expand its influence in the medical device industry, driven by a mission to restore function and improve the quality of life for patients suffering from nerve damage.
DitchCarbon Score
How does Axogen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Axogen's score of 27 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Axogen's reported carbon emissions
In 2022, Axogen, headquartered in the US, reported total carbon emissions of approximately 1,630,000 kg CO2e. This figure includes about 526,000 kg CO2e from Scope 1 emissions and around 1,104,000 kg CO2e from Scope 2 emissions. Notably, there is no reported data for Scope 3 emissions. Despite the significant total emissions, Axogen has not established specific reduction targets or initiatives as part of their climate commitments. The absence of such targets suggests a need for further development in their sustainability strategy. The emissions data is sourced directly from Axogen, Inc., with no cascading from a parent or related organization. As the company continues to operate within the medical technology sector, it is essential for Axogen to enhance its climate commitments and consider setting science-based targets to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 526,000 |
| Scope 2 | 1,104,000 |
| Scope 3 | - |
How Carbon Intensive is Axogen's Industry?
How Carbon Intensive is Axogen's Location?
Axogen's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Axogen has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
